Founded in 2016 and headquartered in San Diego, California, Beacon Discovery is a privately held company that is a world leader in all facets of GPCR-focused drug discovery. Beacon's mission is to efficiently identify and advance molecules targeting GPCRs from concept to clinic. Beacon collaborates with biopharma partners to leverage internally enabled GPCR targets and small molecule modulators as well as its wealth of GPCR discovery skills and tools.  In addition to Takeda, Beacon has established key strategic partnerships with Boehringer Ingelheim, Janssen, and multiple start-up companies.  Beacon also has a number of internal programs focused on therapeutically important targets to address unmet medical needs.